PSMA-RADS-2 differs from PSMA-RADS-1 in the certainty with which a malignant diagnosis can be excluded, with PSMA-RADS-2 representing those lesions where the possibility of a PCa lesion exists, although it is remote (e.g., overlying uptake from an otherwise benign process could mask malignant uptake). This evidence concerns the gene FOLH1 and posterior cortical atrophy.